Artelo Biosciences (ARTL) Q2 2026 earnings summary

Executive summary

• Focused on developing therapeutics targeting lipid-signaling pathways, with three main programs: ART27.13 (cancer anorexia, Phase 2a), ART26.12 (FABP5 inhibitor, Phase 1), and ART12.11 (CBD cocrystal, preclinical).

• No revenue generated to date; expects continued losses as R&D progresses.

• Interim results for ART27.13 showed significant weight gain in cancer patients versus placebo, with a favorable safety profile.

• ART26.12 completed Phase 1 with positive safety and pharmacokinetic results.

Financial highlights

• Net loss for six months ended June 30, 2026: $5.4 million, compared to $5.6 million for the same period in 2025.

• Operating expenses for six months ended June 30, 2026: $5.2 million, down from $5.5 million year-over-year.

• Cash and cash equivalents as of June 30, 2026: $4.2 million, up from $0.6 million at December 31, 2025.

• Weighted average shares outstanding for six months ended June 30, 2026: 1.7 million.

Outlook and guidance

• Expects continued R&D and general and administrative expenses, with future increases tied to clinical development and available funding.

• Substantial doubt exists about ability to continue as a going concern within one year without additional funding.

• Plans to raise additional capital through equity, debt, or licensing.